CMND Clearmind Medicine Inc.
Price Chart
Executive Summary
Clearmind Medicine announced the publication of a Japanese patent application for its MEAI-based depression treatment, expanding its global IP portfolio. This is a routine IP development for a clinical-stage biotech with no revenue, and the filing does not contain financial data or near-term catalysts.
Actionable Insight
This patent filing is a minor positive for IP positioning but does not change the company's near-term outlook. Monitor for clinical trial updates or financing events, as the company has a $2M market cap and likely needs capital.
Key Facts
- Japanese patent application published for MEAI compositions to treat depression.
- MEAI is Clearmind's flagship non-hallucinogenic molecule.
- Company's IP portfolio includes 19 patent families and 31 granted patents.
- No financial data, clinical trial results, or guidance provided in the filing.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company.
Risk Factors
- Patent issuance is not guaranteed and may not be commercially advantageous.
- No revenue or near-term catalysts; high cash burn risk for a $2M market cap company.
- Historical stock volatility is extreme (e.g., -56% T+5 on prior neutral filings).
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-062449 |
| Document: ea029271701ex99-1.htm | 0001213900-26-062449 |
| Document: 0001213900-26-062449-index-headers.html | 0001213900-26-062449 |
| Document: 0001213900-26-062449-index.html | 0001213900-26-062449 |
| Document: 0001213900-26-062449.txt | 0001213900-26-062449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 18, 2026
2d ago
|
6-K
| $3.07 awaiting T+1 | awaiting T+1 | — | $3.07 (−0.00%) |
|
Jun 18, 2026
2d ago
|
Press Release
| $3.05 awaiting T+1 | awaiting T+1 | — | $3.07 (+0.66%) |
|
Jun 16, 2026
4d ago
|
6-K
| $3.14 $3.14 | · 0.00% | ▲ +1.25% | $3.07 (−2.23%) |
|
Jun 12, 2026
8d ago
|
3
| $3.37 $3.14 | ▼ −6.82% | ▼ −6.23% | $3.07 (−8.90%) |
|
Jun 5, 2026
15d ago
|
Press Release
| $3.98 $3.79 | ▼ −4.77% | ▼ −5.00% | $3.07 (−22.86%) |
|
May 29, 2026
22d ago
|
6-K
| $3.58 $3.17 | ▼ −11.45% | ▼ −11.73% | $3.07 (−14.25%) |
|
May 29, 2026
22d ago
|
Press Release
| $3.58 $3.17 | ▼ −11.45% | ▼ −11.73% | $3.07 (−14.25%) |
|
May 26, 2026
25d ago
|
6-K
| $2.59 $2.48 | ▼ −4.25% | ▼ −4.26% | $3.07 (+18.53%) |
|
May 26, 2026
25d ago
|
Press Release
| $2.59 $2.48 | ▼ −4.25% | ▼ −4.26% | $3.07 (+18.53%) |
|
May 19, 2026
4w ago
|
6-K
| $2.36 $2.52 | ▼ −6.78% | ▼ −5.74% | $3.07 (−30.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access